Matthew G. Fury, Sofia Haque, Hilda Stambuk, Ronglai Shen, Diane Carlson and David Pfister A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer Cancer 117
Article first published online: 4 OCT 2010 | DOI: 10.1002/cncr.25464
Treatment with pemetrexed plus gemcitabine every 2 weeks with vitamin support generally was well tolerated in patients with advanced head and neck squamous cell cancer (HNSCC). The results from this study provided further evidence that pemetrexed may have significant palliative activity against advanced HNSCC.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.